S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
LON:FARN

Faron Pharmaceuticals Oy (FARN) Share Price, News & Analysis

GBX 137.50
-2.50 (-1.79%)
(As of 03/28/2024 07:39 PM ET)
Today's Range
130
145
50-Day Range
129
306
52-Week Range
120
370
Volume
40,251 shs
Average Volume
26,977 shs
Market Capitalization
£94.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
FARN stock logo

About Faron Pharmaceuticals Oy Stock (LON:FARN)

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. It also develops Haematokine, an investigational AOC3 inhibitor that is used for regenerative medicines in hematological malignancies, as well as chemotherapy induced suppression of the bone marrow. In addition, the company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.

FARN Stock Price History

FARN Stock News Headlines

Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
Faron Pharmaceuticals Oy (FARN)
Faron Pharmaceuticals Oy (FARN.L)
Faron Pharmaceuticals Oy FARN
Faron Pharma raises €7.1m as cancer study continues apace
Faron Pharma data 'extremely encouraging', says CEO
See More Headlines
Receive FARN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Faron Pharmaceuticals Oy and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
40
Year Founded
N/A

Profitability

Net Income
£-30,940,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£-725,000.00
Cash Flow
GBX 6.88 per share
Book Value
GBX (22) per share

Miscellaneous

Free Float
N/A
Market Cap
£94.61 million
Optionable
Not Optionable
Beta
-0.14
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Juho Markku Jalkanen M.D. (Age 46)
    MSc, Ph.D., Chief Operating Officer
    Comp: $541.04k
  • Dr. Markku Tapani Jalkanen Ph.D. (Age 70)
    Founder, CEO & Executive Director
    Comp: $239.57k
  • Mr. James M. O'Brien CPA
    M.B.A., Chief Financial Officer
  • Dr. Maija Hollmen Ph.D.
    Chief Scientific Officer
  • Mr. Vesa Karvonen L.L.M. (Age 52)
    General Counsel
  • Ms. Jennifer Smith-Parker
    Head of Communications
  • Dr. Juhana Heinonen
    Chief Commercial Officer
  • Dr. Birge Berns M.D.
    Interim Chief Medical Officer

FARN Stock Analysis - Frequently Asked Questions

How have FARN shares performed in 2024?

Faron Pharmaceuticals Oy's stock was trading at GBX 305 at the start of the year. Since then, FARN stock has decreased by 54.9% and is now trading at GBX 137.50.
View the best growth stocks for 2024 here
.

What other stocks do shareholders of Faron Pharmaceuticals Oy own?
How do I buy shares of Faron Pharmaceuticals Oy?

Shares of FARN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:FARN) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners